TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

In a a report made public on Sunday, 24 March, research analysts at BidaskScore’s research division boosted TRACON Pharmaceuticals (NASDAQ:TCON)‘s stock to a “Buy”.

BERGENBIO AS ORDINARY SHARES NORWAY (OTCMKTS:BRRGF) had a decrease of 20.51% in short interest. BRRGF’s SI was 24,800 shares in March as released by FINRA. Its down 20.51% from 31,200 shares previously. It closed at $4.078 lastly. It is down 0.00% since March 25, 2018 and is . It has underperformed by 4.37% the S&P500.

Analysts await TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report earnings on May, 8. They expect $-0.17 earnings per share, up 63.04% or $0.29 from last year’s $-0.46 per share. After $-0.26 actual earnings per share reported by TRACON Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -34.62% EPS growth.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $43.95 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. It currently has negative earnings. The company’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

More notable recent TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news were published by: which released: “TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update – Nasdaq” on February 28, 2019, also with their article: “Tracon +8.6% on positive test results – Seeking Alpha” published on December 26, 2018, published: “TRACON Pharmaceuticals’ Phase 2 TRAXAR trial fails to meet primary endpoints; shares down 21% premarket – Seeking Alpha” on December 21, 2018. More interesting news about TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) were released by: and their article: “TRACON Pharmaceuticals submits IND application for TJ4309 for treatment of advanced solid tumors – Seeking Alpha” published on December 26, 2018 as well as‘s news article titled: “TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference – GlobeNewswire” with publication date: August 29, 2018.

The stock decreased 0.68% or $0.01 during the last trading session, reaching $1.47. About 443,278 shares traded. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 47.35% since March 25, 2018 and is downtrending. It has underperformed by 51.72% the S&P500. Some Historical TCON News: 23/03/2018 – TRACON PHARMACEUTICALS INC – TO USE PROCEEDS TO FUND DEVELOPMENT OF TRC105, TO CONTINUE DEVELOPMENT OF OTHER ASSETS SUCH AS TRC253; 21/03/2018 FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic; 09/04/2018 – TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors; 19/04/2018 – DJ TRACON Pharmaceuticals Inc, Inst Holders, 1Q 2018 (TCON); 09/05/2018 – TRACON Pharmaceuticals 1Q Loss/Shr 46c; 09/05/2018 – THROMBOGENICS NV THR.BR – FIRST PATIENT ENROLLED IN PHASE 2 STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB, LUCENTIS®) IN PATIENTS WITH DME; 10/04/2018 – TRACON PHARMACEUTICALS SAYS REGARDING ELECTION OF TED WANG TO BOARD, BOARD APPROVED AN INCREASE IN SIZE FROM SIX TO SEVEN MEMBERS – SEC FILING; 22/03/2018 – Roche’s Lucentis 0.3 Mg Prefilled Syringe Receives FDA Approval; 23/03/2018 – TRACON Pharmaceuticals Enters into Agreement for $38.7M Private Placement; 21/03/2018 – GENENTECH – PREFILLED SYRINGE OPTIONS ARE NOW FDA-APPROVED FOR ALL LUCENTIS INDICATIONS

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *